Using molecular radiogenomics to improve treatment predictions in lung cancer
Official title: The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer
Run by Buddhist Tzu Chi General Hospital · NCT05541744 · Data updated 2026-11-12
This study is testing if combining special imaging and genetic information can help doctors better predict how well treatments will work for people with non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Buddhist Tzu Chi General Hospital Academic / other |
| Locations | 1 site (Hualien City) |
| Status | Recruiting |
| Started | August 1, 2023 |
| Main results expected | July 31, 2026 |
| Study ends | July 31, 2028 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT05541744 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 20 years and older with a pathological diagnosis of non-small cell lung cancer who have undergone complete staging.
✕Probably not a fit
Patients with other concurrent cancers or those unable to undergo FDG PET/CT imaging may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on non-small cell lung cancer (NSCLC), which is a leading cause of cancer-related deaths. The researchers aim to combine molecular imaging techniques, specifically 18F-FDG PET, with whole exome sequencing to create a more accurate model for predicting treatment responses and survival outcomes. By analyzing tumor biology and genetic alterations, the study seeks to enhance risk stratification for patients undergoing treatment. The study utilizes routine pathological specimens and advanced sequencing technologies to gather comprehensive data on tumor characteristics.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans and improved survival rates for lung cancer patients.
How similar studies have gone: While the combination of radiogenomics is a novel approach, similar studies have shown promise in enhancing predictive models for cancer treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at least 20-years * Pathological proven non-small cell lung cancer and received complete staging work-up * Pre-treatment pathological specimen of the primary tumor Exclusion Criteria: * Coexistence of non-aerodigestive tract cancer. * Unable to comply to FDG PET/CT exam or poor image quality * Unable to determine the primary tumor
Where it's running
-
Hualien Tzu Chi Hospital
Hualien City, Taiwan Recruiting
Study contacts
- Study coordinator: Yu-Hung Chen, M.D.
- Email: jedimasterchen@hotmail.com
- Phone: 886-3-8561825
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.